Steadfast in our commitment and support for HCV elimination by 2030.

At AbbVie, we’re supporting people with HCV by identifying and successfully linking them to appropriate care – one at a time.

We are passionate and committed to finding and treating populations considered among the “missing millions” to achieve the WHO’s target of HCV elimination by 2030.

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

Europe

  • 53,000 people die each year from viral hepatitis.
  • An estimated 10.6 million people live with hepatitis B. Only 16% have been diagnosed, and less than 2% are receiving the treatment they would need.
  • An estimated 8.6 million people live with hepatitis C. Only 29% have been diagnosed, and just 9% are receiving the treatment they would need.